Using NIS2+ ™ to identify at-risk MASH in clinical trials

Jimmy Lai has served as a speaker and advisory board member for Gilead Sciences. Vincent Wong has served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirna; and a speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk, and Unilab. He has received a research grant from Gilead Sciences, and is a co-founder of Illuminatio Medical Technology Limited.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research